An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 Lymphopenia

Background:
Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells called CD4 T cells. The low CD4 T cells renders people with ICL prone to many types of severe infections, autoimmune diseases, and cancers. Although these infections and diseases can be treated whenever occur, there is currently no treatment that targeting the underlying deficiency of CD4 T cells can provide a definitive treatment for people with ICL.
Objective:
To test a new drug (NT-17) in people with ICL which can increase the number of CD4 T cells
Eligibility:
People aged 18 to 75 years with ICL who are also enrolled in NIH protocol 09-I-0102.
Design:
Participants will be screened. They will have a physical exam and blood tests. Some participants with high suspicion of central nervous system infection or history of such infections may also undergo a lumbar puncture. A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.
Participants will receive 3 doses of NT-17, each about 12 weeks apart. NT-17 is injected into the muscle of the upper arm, thigh, or buttock. They will visit the clinic 5 days before each dose and again 2 and 4 weeks after each dose. Blood will be drawn at all visits.
Participants will undergo leukapheresis 3 times. Blood will be drawn from a needle in one arm. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be given back through a second needle in the other arm.
Some visits will include a rectal swab.
Some participants may have additional tests, including a skin exam, skin biopsies, and medical imaging.
Participants will have 3 follow-up visits every 3 months after they finish treatment.

开始日期2024-05-16

申办/合作机构

National Institute of Allergy & Infectious Diseases

[+1]

NCT04054752 / Withdrawn临床1期IIT

A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy

Background:
People with cancer, and especially older people, have a weakened immune system (the defense system of the body). This is often caused by the treatments for cancer. Older cancer survivors are therefore more prone to getting infections, some of which are preventable through vaccines. But because their immune systems are weakened, their response to vaccines is poor. Researchers want to see if a new drug, NT-I7, can help.
Objective:
To see if NT-I7 can boost the immune system.
Eligibility:
Adults 60 and older who have recently finished chemotherapy for breast, colorectal, or bladder cancer.
Design:
Participants will be screened with a physical exam, medical history, and blood and urine samples. Their heart s electrical activity will be checked. They will have an ultrasound of their spleen. They may give a tissue sample from a previous biopsy.
Participants in phase 1a of the study will get 1 dose of NT-I7. It will be given by injection with a needle into the muscle of the upper arm, thigh, or buttocks.
Participants in phase 1b will get 5 vaccines over a few months. They may get an optional booster and/or 6th vaccine. They will also get NT-I7.
Participants will repeat the screening tests during the study. They may get a peripheral intravenous catheter in a vein in their hand or arm for blood draws.
Participants may have apheresis. For this, blood is taken from an arm vein. The white blood cells are separated from the blood. The rest of the blood, minus the white blood cells, is returned into a vein in the other arm. A catheter may be used.
Participants will have follow-up visits for 1 year.

开始日期2023-05-30

申办/合作机构

National Cancer Institute

[+1]

NCT05465954 / Recruiting临床2期

Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.

开始日期2023-01-20

申办/合作机构

Mayo Clinic

[+2]

100 项与依非白介素α 相关的临床结果

登录后查看更多信息

100 项与依非白介素α 相关的转化医学

登录后查看更多信息

100 项与依非白介素α 相关的专利（医药）

登录后查看更多信息

项与依非白介素α 相关的文献（医药）

2024-01-01·Cell Reports Medicine

Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells

Article

作者: Kim, Jong Kyoung ; Chang, Jun ; Lee, Seung-Woo ; Choi, Donghoon ; Choi, Yoon Ha ; Kong, Hyun-Jung ; You, Gihoon ; Baek, Seungtae ; Kim, Young-Min ; Kwon, Dong-Il ; Oh, Youngsik ; Min, Jeongyong ; Lee, Kun-Joo ; Song, Manki ; Jeong, Yujin L ; Choi, Youngwon ; Jeong, Chaerim ; Choi, Jung-Ah ; Kang, Yeon-Woo ; Im, Sun-Kyoung ; Lee, Changhyung ; Park, Subin

Repeated pandemics caused by the influenza virus and severe acute respiratory syndrome coronavirus (SARS-CoV) have resulted in serious problems in global public health, emphasizing the need for broad-spectrum antiviral therapeutics against respiratory virus infections. Here, we show the protective effects of long-acting recombinant human interleukin-7 fused with hybrid Fc (rhIL-7-hyFc) against major respiratory viruses, including influenza virus, SARS-CoV-2, and respiratory syncytial virus. Administration of rhIL-7-hyFc in a therapeutic or prophylactic regimen induces substantial antiviral effects. During an influenza A virus (IAV) infection, rhIL-7-hyFc treatment increases pulmonary T cells composed of blood-derived interferon γ (IFNγ)+ conventional T cells and locally expanded IL-17A+ innate-like T cells. Single-cell RNA transcriptomics reveals that rhIL-7-hyFc upregulates antiviral genes in pulmonary T cells and induces clonal expansion of type 17 innate-like T cells. rhIL-7-hyFc-mediated disease prevention is dependent on IL-17A in both IAV- and SARS-CoV-2-infected mice. Collectively, we suggest that rhIL-7-hyFc can be used as a broadly active therapeutic for future respiratory virus pandemic.

2023-12-01·Leukemia

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies

Article

作者: Cooper, Matthew L ; O' Neal, Julie ; Staser, Karl W ; Carter, Alun J ; DiPersio, John F ; Ritchey, Julie K ; Turk, Rolf ; Devenport, Jessica M ; Rettig, Garrett ; Lee, Byung Ha ; Rettig, Michael P ; Xiang, Jingyu ; Gao, Feng ; Kim, Miriam Y

Abstract:

T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells in pan T-cell malignancies, we developed an allogeneic “universal” CD2-targeting CAR-T cell (UCART2), in which the CD2 antigen is deleted to prevent fratricide, and the T-cell receptor is removed to prevent GvHD. UCART2 demonstrated efficacy against T-ALL and CTCL and prolonged the survival of tumor-engrafted NSG mice in vivo. To evaluate the impact of CD2 on CAR-T function, we generated CD19 CAR-T cells (UCART19) with or without CD2 deletion, single-cell secretome analysis revealed that CD2 deletion in UCART19 reduced frequencies of the effector cytokines (Granzyme-B and IFN-γ). We also observed that UCART19ΔCD2 had reduced anti-tumor efficacy compared to UCART19 in a CD19+NALM6 xenograft model. Of note is that the reduced efficacy resulting from CD2 deletion was reversed when combined with rhIL-7-hyFc, a long-acting recombinant human interleukin-7. Treatment with rhIL-7-hyFc prolonged UCART2 persistence and increased survival in both the tumor re-challenge model and primary patient T-ALL model in vivo. Together, these data suggest that allogeneic fratricide-resistant UCART2, in combination with rhIL-7-hyFc, could be a suitable approach for treating T-cell malignancies.

2023-10-24·Blood advances

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.

Article

作者: Ritchey, Julie K ; Street, Emily ; Rettig, Mike P ; Haas, Gabriel J ; Amayta, Parmeshwar N ; Cooper, Matthew L ; Carter, Alun ; Zhou, Alice ; DiPersio, John F ; Fehniger, Todd A ; Choi, Donghoon ; Berrien-Elliott, Melissa ; Gladney, Susan ; González, L Sofía ; Lee, Byung Ha ; O'Neal, Julie ; Niswonger, Jessica ; Gao, Feng

Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric antigen receptor (CAR) therapy because of its high expression in most MM, with limited expression in other cell types, resulting in favorable on-target, off tumor toxicity. The response rate to autologous BCMA CAR-T therapy is high; however, it is not curative and is associated with risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. Outcomes in patients treated with BCMA CAR-T cells (CAR-Ts) may improve with allogeneic CAR T-cell therapy, which offer higher cell fitness and reduced time to treatment. However, to prevent the risk of graft-versus-host disease (GVHD), allogenic BCMA CAR-Ts require genetic deletion of the T-cell receptor (TCR), which has potential for unexpected functional or phenotype changes. Invariant natural killer T cells (iNKTs) have an invariant TCR that does not cause GVHD and, as a result, can be used in an allogeneic setting without the need for TCR gene editing. We demonstrate significant anti-myeloma activity of BCMA CAR-iNKTs in a xenograft mouse model of myeloma. We found that a long-acting interleukin-7 (IL-7), rhIL-7-hyFc, significantly prolonged survival and reduced tumor burden in BCMA CAR-iNKT-treated mice in both primary and re-challenge settings. Furthermore, in CRS in vitro assays, CAR-iNKTs induced less IL-6 than CAR-Ts, suggesting a reduced likelihood of CAR-iNKT therapy to induce CRS in patients. These data suggest that BCMA CAR-iNKTs are potentially a safer, effective alternative to BCMA CAR-Ts and that BCMA CAR-iNKT efficacy is further potentiated with rhIL-7-hyFc.

项与依非白介素α 相关的新闻（医药）

2024-04-09

·PRNewswire

NeoImmuneTech's NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting

NT-I7 maintains cancer-specific T-cell amplifying efficacy when combined with standard of care colorectal cancer therapy FOLFOX® Study indicates interest for potential combination therapy with chemotherapeutic agents. ROCKVILLE, Md., April 9, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT), a global leader in T-cell-based immunotherapy, today presented a poster on a pre-clinical study that opens a new field of potential applications for NT-I7 (efineptakin alfa). The poster was presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (April 5-10, 2024, San Diego, CA). The study explored the efficacy of NT-I7 (efineptakin alfa) in combination with FOLFOX® (a combination of 5-fluorouracil, leucovorin, and oxaliplatin), a first-line standard of care (SoC) for colorectal cancer, in an animal model of colorectal cancer (MC38, C57BL/6 mice). The study's findings suggest a significant improvement in treatment outcomes when NT-I7 is used alongside FOLFOX®, demonstrating a 69% reduction in tumor size compared to the administration of FOLFOX® alone. While the overall Absolute Lymphocyte Count (ALC) in the blood was reduced by FOLFOX® treatment, the number of anti-cancer specific T cells in the tumor was significantly increased in the combination group compared to FOLFOX® alone. Dr. Luke Oh, President and CEO of NeoImmuneTech said: "We are very excited by results that shows NT-I7 might be effective in combination with cytotoxic chemotherapeutic agents. As chemotherapeutic agents are still the standard of care for most early-stage cancer indications, combining NT-I7 with various chemotherapeutic agents might bring new hope to patients in situations where immuno-oncology is not used." About Colorectal Cancer Colorectal cancer is the third most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide. It often begins with growths on the inner lining of the colon or rectum called polyps, which can change into cancer over time. Colorectal cancer affects more than 150,000 people in the US and 1.8 million people worldwide each year. Despite progress in treatment in the last decade, the 5-year survival rate is still only 63% overall and a meager 13% for patients with metastatic disease. About NT-I7 (efineptakin alfa) (rhIL-7-hyFc) NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications. About NeoImmuneTech, Inc. NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity. NIT is led by a strong executive team and talented members with rich industry experience. NIT is expanding rapidly in its operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit . Forward-looking Statements The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the "Company") that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company's control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein. Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties, and is subject to change based on various factors. SOURCE The NeoImmuneTech, Inc

免疫疗法AACR会议临床研究临床结果

2024-04-02

·BioSpace

NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT). Having joined the company as President in January 2024, Dr. Oh now succeeds Dr. Se Hwan Yang, Ph.D., as Chief Executive Officer of NeoImmuneTech, Inc. In his new role, Dr. Oh will lead NeoImmuneTech from its Rockville headquarters and overview all the operations in Korea. Dr. Oh is an expert in regulatory policies and drug development, encompassing both biologics and small molecules. He brings over six years of regulatory experience at the U.S. FDA. His recent tenure at Samsung Bioepis as Vice-President in charge of Regulatory Development was marked by a number of successful preparation and submission of biosimilar applications to regulatory agencies in the US, EU, UK, and Canada. Prior to this position, he has worked as Senior Staff Fellow at the U.S. FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology, and he has held various roles in research and development for leading organizations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences, and Vertex Pharmaceuticals. Dr. Oh has a Ph.D. in Neuroimmunology from the McGill University (Montreal, Canada). Dr. Luke Oh, Ph.D. President and Chief Executive Officer of NeoImmuneTech, Inc. said: "It is an honor to lead NeoImmuneTech into the future, particularly as our main asset, NT-I7, a unique long-acting human IL-7, moves closer to potentially being the first approved treatment for Acute Radiation Syndrome (ARS). I am committed to advancing the work that Dr. Se Hwan Yang initiated, aligning the company on our business priorities, and stepping up this new phase of NeoImmuneTech." About NT-I7 (efineptakin alfa) (rhIL-7-hyFc) NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety pro making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications. About NeoImmuneTech, Inc. NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit . Forward-looking Statements The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the "Company") that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company's control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein. Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors. Photo - View original content to download multimedia: SOURCE The NeoImmuneTech, Inc

高管变更免疫疗法放射疗法

2024-03-18

·Science Daily

Addressing both flu and COVID-19 through a single, multitasking injection

Researchers have identified new drug candidates for preventing and treating major respiratory viral infections. In preparation for the winter season last year, the Korean Medical Association recommended that people with compromised immune systems receive both the flu and COVID-19 vaccines simultaneously. The prospect of receiving shots in both arms may have been a shock, especially for children. However, there is now exciting news about a multitasking substance capable of preventing and treating both flu and COVID-19 infections concurrently, and it is gaining momentum. Professor Seung-Woo Lee from the Department of Life Sciences and the School of Convergence Science and Technology, Subin Park and Yujin Jeong, PhD candidates from the Department of Life Sciences at Pohang University of Science and Technology (POSTECH), and Dr. Donghoon Choi from NeoImmuneTech (CEO Sehwan Yang) collaborated with the Gyeongbuk Institute for Bio Industry and the International Vaccine Institute to identify new drug candidates for preventing and treating major respiratory viral infections. This research has recently been published in the international journal Cell Reports Medicine. In recent times, a global resurgence of infections has been observed, predominantly linked to a novel variant of COVID-19 known as 'JN.1'. The Korean Disease Control and Prevention Agency reports that this variant has become the dominant strain in Korea, surpassing a detection rate of 50%. While vaccines prove effective against specific viruses, the emergence of new variants necessitates considerable time for the development of corresponding vaccines, leading to potential public health crises as witnessed during the COVID-19 pandemic. To address this challenge, there is a pressing need for more broadly applicable treatments capable of swiftly responding to the ongoing mutations. The research team explored the potential application of the long-acting recombinant cytokine protein rhIL-7-hyFc (NT-I7; efineptakin alfa), currently undergoing clinical development as an immunotherapy drug. This exploration aimed to assess its suitability as a treatment for major respiratory viruses due to its capacity to activate diverse immune cells within the respiratory tract. In experimental settings, the protein triggered the influx of acquired T cells and the proliferation of innate-like T cells in the lungs. These innate-like T cells demonstrated a swift and comprehensive defense against a broad spectrum of pathogens, functioning as if they were deploying inherent mechanisms. Consequently, the treatment exhibited both therapeutic and preventive effects against COVID-19, influenza virus, respiratory syncytial virus, and others. Notably, the drug candidates were not tailored to a specific virus but demonstrated universal applicability to major respiratory diseases. Professor Seung-Woo Lee, leading the study, stated, "Through collaborative study involving industry, academia, and the research community, we have discovered insights to prepare for future respiratory virus pandemics." He added, "We are committed to advancing our efforts to transform the prospect of a universal treatment, capable of controlling co- and serial infections of respiratory viruses and bacteria, into a reality." The research was sponsored by the Infectious Disease Prevention and Treatment Technology Development Program of the Ministry of Health and Welfare, the Mid-Career Researcher Program of the National Research Foundation of Korea, and the Bio-Industrial Technology Development Project of the Ministry of Trade, Industry and Energy.

疫苗临床研究免疫疗法

100 项与依非白介素α 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11957	-	-	DB16395

研发状态

适应症	最高研发状态	国家/地区	公司
胶质母细胞瘤	临床2期	中国香港更多	BINEX Co., Ltd. 更多
晚期恶性实体瘤	临床2期	美国更多	NeoImmuneTech, Inc. 更多
三阴性乳腺癌	临床2期	中国更多	-
新型冠状病毒感染	终止	-	Washington University School of Medicine 更多
晚期胃食管交界处腺癌	终止	美国更多	NeoImmuneTech, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05286060 (GENUINE, ASCO2023) 人工标引	临床2期	人乳头瘤病毒相关的头颈部鳞状细胞癌新辅助 HPV-16 Positive \| HPV-18 Positive	11	GX-I7+GX-188E+pembrolizumab	壓糧蓋觸壓鹹廠繭窪鹽(構願鹽艱製鏇衊糧築衊) = 顧膚製遞遞構積簾壓蓋窪獵範夢鏇廠糧鏇醖壓 (鏇襯膚鹽構齋淵窪鏇簾 ) 更多	积极	2023-05-26
ASH2022 人工标引	临床1期	复发性弥漫性大B细胞淋巴瘤	7	Tisagenlecleucel+Efineptakin Alfa	廠網壓衊構構網範襯範(獵淵鬱繭糧願鏇艱觸淵) = 鑰積範衊鏇齋襯鬱衊壓鹹網淵製鏇鏇窪鹹鏇艱 (網構窪蓋繭齋範壓範繭 ) 更多	积极	2022-11-15
NCT03687957 (SITC2022) 人工标引	临床1/2期	高级别胶质瘤	19	NT-I7	選憲餘憲廠觸築繭餘醖(獵蓋選壓鹹鹽餘淵範範) = NT-I7 was well-tolerated with grade 1/2 injection site reactions (42%) the most common treatment-related adverse event (TRAE). 製積憲鬱獵網選糧觸網 (艱範膚顧蓋鹹齋鏇製鑰 ) 更多	积极	2022-11-01
NCT03687957 (SITC2022) 人工标引	临床1/2期	高级别胶质瘤	19	NT-I7 (harder-to-treat unmethylated GBM patients)		积极	2022-11-01
NCT04332653 (P-54, ESMO_GI2022)	临床2期	微卫星稳定型结直肠癌	28	NT-I7 + Pembrolizumab	鏇範鑰繭製鹽夢積淵範(選構積遞夢廠築鬱鏇積) = Treatment-related adverse events (trAEs) occurred in 27 (96.4%) subjects, 12 (42.8%) G1-2 events and 14 (50%) G3 events; 1 (3.6%) G4 and no G5 trAEs were reported. No subjects discontinued from the study due to trAE 糧鏇鏇製鏇觸築選衊淵 (簾餘顧鑰範願製醖齋鹹 ) 更多	-	2022-07-02
NCT04332653 (P-54, ESMO_GI2022)	临床2期	微卫星稳定型结直肠癌	28	Pembrolizumab		-	2022-07-02
NCT04332653 (P-48, ESMO_GI2022)	临床2期	胰腺癌	32	NT-I7	願鹹築衊蓋餘襯選憲構(糧製餘範艱範艱繭鹹淵) = NT-I7 treatment-related adverse events (trAEs) occurred in 23 (71.9%) subjects, 18 (56.2%) G1-2, 3 (9.4%) G3; 2 (6.3%) G4; no G5 trAEs were reported 繭鹽廠廠積構窪衊鏇膚 (選選鏇鬱鑰廠選網夢襯 )	-	2022-07-02
NCT04332653 (KEYNOTE A60, ASCO2022) 人工标引	临床2期	HR阳性/HER2低表达实体瘤	92	pembrolizumab+NT-I7 (PDAC)	築糧淵憲壓願鬱網膚衊(願範淵廠鬱夢醖遞獵範) = 構夢襯糧蓋夢觸範餘鏇築獵膚窪製鹽願鹽構獵 (鹽鬱願遞築蓋選襯壓夢 ) 更多	积极	2022-06-02
NCT04332653 (KEYNOTE A60, ASCO2022) 人工标引	临床2期	HR阳性/HER2低表达实体瘤	92	pembrolizumab+NT-I7 (MSS-CRC)	築糧淵憲壓願鬱網膚衊(願範淵廠鬱夢醖遞獵範) = 廠窪簾鹽顧衊壓遞鹽鹹築獵膚窪製鹽願鹽構獵 (鹽鬱願遞築蓋選襯壓夢 ) 更多	积极	2022-06-02
NCT03752723 (KEYNOTE-899, ASCO2022) 人工标引	临床1/2期	三阴性乳腺癌	84	GX-I7+pembrolizumab (phase 1b)	鬱鏇夢餘構齋遞艱積鏇(遞鹽遞壓襯艱憲蓋膚鏇) = GX-I7 1,200 µg/kg Q9W 鏇膚衊選範製構淵鬱蓋 (遞遞夢構餘壓蓋蓋襯遞 ) 更多	积极	2022-06-02
NCT03752723 (KEYNOTE-899, ASCO2022) 人工标引	临床1/2期	三阴性乳腺癌	84	GX-I7+pembrolizumab (phase 2)		积极	2022-06-02
NCT03901573 (ASCO2022)	临床1/2期	皮肤肿瘤	16	NT-I7	觸鏇糧衊鬱築壓鏇選鏇(鬱選膚壓壓網膚觸窪觸) = 齋範願網遞遞積願壓積觸醖夢繭築憲遞鏇壓夢 (簾鹽願顧憲淵齋餘廠壓 )	-	2022-06-02
NCT04332653 (KEYNOTE A60, ASCO2021) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	-	NT-I7+Pembrolizumab	衊憲鹹鑰鹹遞繭廠顧艱(願遞獵製夢網鏇製齋觸) = NT-I7 1200 µg/kg IM Q6W + pembro 200 mg IV Q3W 壓鹽窪齋醖壓衊醖餘廠 (觸淵顧糧艱廠襯鏇繭製 ) 更多	积极	2021-05-28
NCT03687957 (ASCO2021)	临床1/2期	胶质瘤	19	NT-I7	觸鹹願鹹鹽壓簾獵膚鹹(餘壓襯構窪積簾製憲觸) = 蓋蓋鹹廠夢選鏇鹽襯膚醖艱廠膚鹹膚鹹糧壓衊 (餘夢構簾遞選鏇網憲醖 )	-	2021-05-28